You are here

Nat Rev Clin Oncol DOI:10.1038/s41571-021-00479-z

Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.

Publication TypeJournal Article
Year of Publication2021
AuthorsJan, M, Sperling, AS, Ebert, BL
JournalNat Rev Clin Oncol
Date Published2021 Mar 02
ISSN1759-4782
Abstract

For decades, anticancer targeted therapies have been designed to inhibit kinases or other enzyme classes and have profoundly benefited many patients. However, novel approaches are required to target transcription factors, scaffolding proteins and other proteins central to cancer biology that typically lack catalytic activity and have remained mostly recalcitrant to drug development. The selective degradation of target proteins is an attractive approach to expand the druggable proteome, and the selective oestrogen receptor degrader fulvestrant served as an early example of this concept. Following a long and tragic history in the clinic, the immunomodulatory imide drug (IMiD) thalidomide was discovered to exert its therapeutic activity via a novel and unexpected mechanism of action: targeting proteins to an E3 ubiquitin ligase for subsequent proteasomal degradation. This discovery has paralleled and directly catalysed myriad breakthroughs in drug development, leading to the rapid maturation of generalizable chemical platforms for the targeted degradation of previously undruggable proteins. Decades of clinical experience have established front-line roles for thalidomide analogues, including lenalidomide and pomalidomide, in the treatment of haematological malignancies. With a new generation of 'degrader' drugs currently in development, this experience provides crucial insights into class-wide features of degraders, including a unique pharmacology, mechanisms of resistance and emerging therapeutic opportunities. Herein, we review these past experiences and discuss their application in the clinical development of novel degrader therapies.

DOI10.1038/s41571-021-00479-z
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/33654306?dopt=Abstract

Alternate JournalNat Rev Clin Oncol
PubMed ID33654306